E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10038738 |
E.1.2 | Term | Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess indacaterol 300 600 g o.d. via SDDPI superiority in patients with COPD as compared to placebo with respect to 24 h post dose trough FEV1 after 12 weeks of treatment. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effect of indacaterol 300 600 g o.d. on the percentage of days of poor control reported over the 52 week randomized treatment period, as compared to placebo. Important To evaluate the effect of indacaterol 300 600 g o.d. on the total score of the St Georges Respiratory Questionnaire SGRQ , as compared with placebo after 12 weeks treatment as compared with placebo. To evaluate the effect of indacaterol 300 600 g o.d. on time to first COPD exacerbation during the 52 week randomized treatment period as compared with placebo. Other To evaluate the effect of indacaterol 300 600 g o.d. on health related quality of life measures, as compared with placebo after 4, 8, 12 excluding SGRQ, 24, 44 and 52 weeks treatment. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Male and female adults aged 40 years; Co-operative outpatients with a diagnosis of COPD according to the GOLD Guidelines 2005 and a Smoking history of at least 20 pack years b Pre-bronchodilator FEV1 65 of the predicted normal value and at least 0.75 L. This criterion for FEV1 must be demonstrated after a washout period of at least 6 h during which no short-acting beta2-agonist has been inhaled, and 48 h for long-acting beta2-agonists. c Pre-bronchodilator FEV1/FVC 70 |
|
E.4 | Principal exclusion criteria |
1. Pregnant or nursing lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotrophin laboratory test 5 mIU/mL 2. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of postmenopausal 12 months of natural spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels 40 mIU/mL OR are using one or more of the following acceptable methods of contraception a surgical sterilization e.g., bilateral tubal ligation, hysterectomy b hormonal contraception implantable, patch, oral c double-barrier methods any double combination of IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap Acceptable methods of contraception may include total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance. Periodic abstinence e.g., calendar, ovulation, symptothermal, postovulation methods and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation. 3. Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period 4. Patients requiring long term 6 months oxygen therapy for chronic hypoxemia. prn use up to 10 h total in any given 24 h period is acceptable. Nocturnal oxygen use is permitted for patients who reside in a location where the elevation is 8805; 1500 meters 5000 feet above sea level 5. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1. Patients who develop a respiratory tract infection between Visit 1 and Visit 3 must discontinue from the trial, but may be permitted to re-enroll at a later date at least 6 weeks after the start of the respiratory tract infection . 6. Patients with concomitant pulmonary disease, pulmonary tuberculosis unless confirmed by chest x-ray to be no longer active or clinically significant bronchiectasis 7. Patients with a history up to and including Visit 1 of asthma indicated by but not limited to a Blood eosinophil count 400/mm3 b Onset of respiratory symptoms prior to age 40 years 8. Patients with diabetes Type I or uncontrolled diabetes Type II including patients with a history of blood glucose levels consistently outside the normal range or HbA1c 8.0 of total Hb measured at Visit 1 9. Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition such as but not limited to unstable ischemic heart disease, arrhythmia excluding stable AF , uncontrolled hypertension, uncontrolled hypo- and hyperthyroidism, hypokalemia, hyperadrenergic state or any condition which in the investigator s opinion might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study 10. Any patient with lung cancer or a history of lung cancer 11. Any patient with active cancer or a history of cancer with less than 5 years disease free survival time whether or not there is evidence of local recurrence or metastases . Localized basal cell carcinoma without metastases of the skin is acceptable. Patients with a history of cancer excluding lung cancer and 5 years or more disease free survival time may be included in the study by agreement with Novartis Headquarters personnel on a case-by-case basis. 12. Pls see protocol |
|
E.5 End points |
E.5.1 | Primary end point(s) |
This study is designed to provide pivotal confirmation of efficacy and long term safety data for the 300 600 g o.d. doses of indacaterol in COPD. To assess indacaterol 300 600 g o.d. via SDDPI superiority in patients with COPD as compared to placebo with respect to 24 h post dose trough FEV1 after 12 weeks of treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |